Abstract
Background Children with dental caries (tooth decay), the world’s most prevalent noncommunicative disease, face negative impacts on health and quality of life. School-based caries prevention can increase access to care and reduce health inequities.
Methods The CariedAway project was a school-based oral health program and pragmatic clinical trial of minimally-invasive treatments for dental caries. We present data on disease severity and the impacts of the COVID-19 pandemic on the urgent dental needs of high-risk children.
Results 4718 subjects were randomized and treated prior to the COVID-19 pandemic and 1398 completed their first follow-up observation after two years, during which the project was suspended due to infection control policies. Approximately 30% had untreated caries on any dentition at baseline and only 11% of children presented with evidence of having received preventive dental sealants. After 24 months, 4% of children had developed fistula and nearly 10% presented with pulpal involvement.
Conclusion There are severe unmet needs in minority urban children that are further exacerbated by a lack of access to care during disease outbreaks. School-based programs using essential medicines can provide lasting care during pandemic periods.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03442309
Clinical Protocols
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-2891-1
Funding Statement
Research reported in this publication was funded through a Patient-Centered Outcomes Research Institute (PCORI) award (PCS-1609-36824). The content is solely the responsibility of the authors and does not necessarily reflect the official views of the funding organization, New York University, or the NYU College of Dentistry.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval from the New York School of Medicine Institutional Review Board (#i17-00578)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
New analyses, new results, new frame
Data Availability
CariedAway is an active trial. Data requests will be reviewed and may be available upon approval.
